Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,845 total articles
Stagwell's shift from traditional agency work toward AI-enabled digital transformation and a turbocharged Marketing Cloud business is producing tangible revenue and cash-flow improvements. The shares trade at a reasonable price-to-sales on a $2.9B revenue base, while momentum indicators and sizable insider/fund buys point to further upside. This is…
GE Aerospace checks a rare combination: heavy commercial backlog, clear production investment, strong free cash flow, and technically constructive price action. I lay out an actionable long trade with entry, stop and target for a 180-trading-day horizon and explain the thesis, valuation framing, catalysts and risks.
Consumers Bancorp reported Q4 FY2025 results showing net income up 9.0%, a net interest margin of 3.39% and 7.2% loan growth while expanding branches in Ohio. Technicals show strong momentum but an overbought RSI. This is a tactical long trade for active accounts with an explicit entry, stop and target and a mid-term horizon (45 trading days).
ADMA Biologics has taken a beating on accounting allegations and a sharp reevaluation of recent growth. That pain is priced in: EV/EBITDA sits near 10 and free cash flow is roughly $116M. We lay out a mid-term swing trade that buys the post-reset story while explicitly protecting downside around structural support.
Definium Therapeutics has the makings of a classic biotech asymmetric trade: a mid-cap market cap of roughly $5.7B, low leverage, heavy short interest, and an upcoming September 2026 catalyst tied to its CNS program. If the market validates the reported positive DT120 oral disintegrating tablet (ODT) data across two indications, upside to the mid-$…
Caledonia's Q2 production beats and the Bilboes reserve read strengthen the fundamental story. The stock looks attractively valued at a $538M market cap and a PE of ~6.8, but lingering Zimbabwe royalty / tax uncertainty, legal scrutiny, and execution risk on growth projects argue for a tactical, mid-term long rather than a buy-and-hold.
National Energy Services Reunited (NESR) has moved from cyclic recovery to execution: new cementing wins, improving revenue scale and shrinking volatility justify a higher multiple. We lay out a swing trade with entry, stop and target, explain the fundamental rationale and list catalysts and risks.
Lumentum (LITE) has been one of 2025-26's biggest winners, but the bull case isn't purely momentum — hyperscaler capex, Nvidia strategic commitments, and a multi-year silicon-photonics bottleneck argue for durable demand. Valuation is rich on headline multiples, yet the market is paying today for a potential oligopoly supplier of high-bandwidth opt…
Alexandria Real Estate Equities (ARE) offers an attractive risk-reward today: a recurring quarterly payout that equates to a 5.9% yield at current prices, a price-to-book near 0.53 that implies roughly a 50% discount to tangible book, and an enterprise valuation that feels stretched only because of temporary operating headwinds. This trade idea lay…
Grail's failed NHS Galleri readout on 08/01/2026 triggered headline selling across genomic names. Illumina (ILMN) has been swept up, but the company still generates strong free cash flow ($931M), carries manageable leverage (debt/equity ~0.7), and trades near $192.93 with a market cap of about $29.13B. This trade idea lays out an actionable long: e…
CytomX (CTMX) is a clinical-stage oncology biotech advancing varsetatug masetecan (Varseta-M) with upside driven by clinical progress and partnership milestones. A $250M equity raise in March 2026 and a June expansion of the Regeneron collaboration meaningfully reduce near-term dilution risk and extend runway, creating a favorable risk-reward for a…
Greggs is a resilient, cash-generative UK bakery chain trading at a valuation that looks fair but not demanding. A disciplined long entry here balances upside from execution and new product momentum against macro and commodity risks. Trade plan: enter at $25.00, target $30.00, stop $21.00 — horizon: long term (180 trading days).
Cognex (CGNX) is a profitable, cash-generative machine vision leader that the market appears to be discounting relative to its exposure to AI-driven data center and semiconductor supply chains. Strong margins, zero financial debt, and $268M in free cash flow underpin a long-term trade with a favorable risk-reward.
Watts Water Technologies is benefiting from AI-driven data-center infrastructure demand and a recovering Europe after a tough 2025. With a $14.2B market cap, clean balance sheet and strong free cash flow, the stock looks set to re-rate. This is a tactical long idea with a mid-term (45 trading days) horizon: enter on strength at $386.37, stop at $36…
908 Devices makes small, mission-critical mass spectrometers used by customs, food labs, and biotech clients. Recent contract wins and steady top-line growth (Q2 2025 revenue $13.0M, +14% YoY) alongside a manageable enterprise value (~$346M) support a tactical long. Expect near-term volatility; plan for a defined entry, stop and target over a 180 t…
Excelerate Energy is executing an asset-recycling strategy that converts merchant LNG exposure into fee-like, contracted regas capacity via FSRUs and terminal stakes. At roughly $36/share the stock trades at modest multiples (EV/EBITDA ~3.8, P/S 0.75) while recent deals and EBITDA beats show the model can scale. This trade captures a path to higher…
Descartes reported a clean Q1 with 15% revenue growth and expanding operating margin; combined with $377M cash and targeted AI acquisitions, the setup favors a long trade. Valuation is rich but justified by recurring SaaS revenue, network effects and steady free cash flow. Entry $77.00, stop $70.00, target $95.00 over a long-term (180 trading days)…
Sphere Entertainment (SPHR) is trading near its 52-week high as the company converts a unique venue into a content and advertising platform. Strong cash flow, modest leverage and visible revenue ramps from ticketing, Exosphere advertising and licensing justify a constructive trade. This idea is actionable with a clear entry at $173.85, a stop at $1…
Astera Labs is trading on momentum after AWS' AI strength and the company’s own accelerating revenue and cash generation. With profitable margins, a debt-free balance sheet and improving technicals, ALAB offers an asymmetric risk/reward for a disciplined swing trade. Entry $332.63, stop $305.00, target $420.00 — mid-term horizon (45 trading days).
CECO Environmental (CECO) has delivered on the two biggest near-term items investors were watching: a strengthened orders outlook and a strategic merger with Thermon that adds scale and cross-selling opportunity. Fundamentals remain mixed — high valuation and modest free cash flow — but the combination, order growth target (> $1.5B), and improving …
Reports that Riot Platforms may be linked to a $9.1 billion Anthropic deal are unconfirmed but consequential. Given Riot's $7.9B market cap, heavy hash-rate growth, and under-levered balance sheet, a confirmed AI partnership or large contract would materially change valuation expectations. This trade idea outlines a long entry at $21.07, a conserva…
Damora (DMRA) is trading at $31.27 with a market cap near $2.0B and a cash-rich balance sheet. Competition that validates galectin-3/LOXL2 biology de-risks the thesis while internal programs and corporate actions create multiple paths to upside. This is a medium-risk long trade: enter near $31.27, stop at $27.00, target $38.00 over a position horiz…
AMAL has run up to the low $50s, trading at a P/E in the low teens and a market cap near $1.52B, but consensus 12-month analyst targets sit around $30. A technical stall at the 52-week high and declining short-interest trajectory set up a trade that profits if the name re-rates toward analyst levels. We lay out an entry, stop, targets and the key c…
Butterfly Network has moved from gadget to platform: a $2.95B market cap, strong balance-sheet ratios, and accelerating adoption of AI-enabled point-of-care imaging support a long trade. Entry at $9.22 with a $13.00 target and $7.50 stop, held over a 120 trading-day horizon, balances upside from software/recurring revenue with the valuation and ins…
Eli Lilly’s next-generation obesity candidate retatrutide and a blistering Q2 performance force a reassessment. The market has priced growth into a premium multiple, but retatrutide’s efficacy (28.3% mean weight loss in Phase 3) plus robust cash generation and raised guidance make a compelling asymmetric long. This trade idea lays out an entry at $…
